Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the diabetes control and complications trial: A randomized, controlled trial

Annals of Internal Medicine

Volumn 128, Issue 7, 1998, Pages 517-523

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC RETINOPATHY; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; LIFE TABLE; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0032055459     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-128-7-199804010-00001     Document Type: Article

References (23)

1. Ludvigsson J, Heding LG. Beta-cell function in children with diabetes. Diabetes. 1978;27(Suppl 1):230-4.
2. Madsbad S, Krarup T, Regeur L, Faber OK, Binder C. Effect of strict blood glucose control on residual beta-cell function in insulin-dependent diabetics. Diabetologia. 1981;20:530-4.
3. Krarup T, Madsbad S. Effect of two periods with intensified insulin treatment on B-cell function during the first 18 months of type 1 (insulin-dependent) diabetes mellitus. Diabete Metab. 1986;12:256-60.
4. de Beaufort CE, Bruining GJ, Aarsen RS, den Boer NC, Grose WF. Does continuous subcutaneous insulin infusion (CSII) prolong the remission phase of insulin-dependent diabetic children? Preliminary findings of a randomized prospective study. Neth J Med. 1985;28:53-4.
5. Bergenstal RM, Dupre J, Lawson PM, Rubenstein AH. Observations on C-peptide and free insulin in the blood during continuous subcutaneous insulin infusion and conventional insulin therapy. Diabetes. 1985;34(Suppl 3): 31-6.
6. Perlman K, Ehrlich RM, Filler RM, Albisser AM. Sustained normoglycemia in newly diagnosed type I diabetic subjects. Short-term effects and one-year follow-up. Diabetes. 1984;33:995-1001.
7. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-86.
8. The Diabetes Control and Complications trial (DCCT). Design and methodological considerations for the feasibility phase. The DCCT Research Group. Diabetes. 1986;35:530-45.
9. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observation during eligibility testing for the Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. J Clin Endocrinol Metab. 1987;65:30-6.
10. Steffes M, Tamborlane W, Becker D, Palmer J, Cleary P. The effect of intensive diabetes treatment on residual beta cell function in the Diabetes Control and Complications Trial (DCCT) [Abstract]. Diabetes. 1996;46(Suppl 2):18A.
11. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18:361-76.
12. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial (DCCT): a multicenter study. The DCCT Research Group. Clin Chem. 1987;33:2267-71.
13. Wei LJ, Lachin JM. Two-sample asymptotically distribution-free tests for incomplete multivariate observations. Journal of the American Statistical Association. 1984;79:653-61.
14. Lee ET. Statistical Methods for Survival Data Analysis. Belmont, CA: Lifetime Learning; 1980:88-92, 127-9.
15. McCullagh P, Nelder JA. Generalized Linear Models. 2d ed. New York: Chapman & Hall; 1989:194-200, 429-30.
16. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995;44:968-83.
17. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int. 1995;47: 1703-20.
18. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996;45:1289-98.
19. Leahy JC. Natural history of β-cell dysfunction. Diabetes Care. 1990;13:992-1010.
20. Kernell A, Ludvigsson J, Finnström K. Vitreous fluorophotometry in juvenile diabetics with and without retinopathy in relation to metabolic control: insulin antibodies and c-peptide levels. Acta Ophthalmol (Copenh). 1990;68: 415-20.
21. Wahren J, Johansson BL, Wallberg-Henriksson H, Linde B, Fernqvist-Forbes E, Zierath JR. C-peptide revisited - new physiological effects and therapeutic implications. J Intern Med. 1996;240:115-24.
22. Wahren J, Johansson BL, Wallberg-Henriksson H. Does C-peptide have a physiological role? Diabetologia. 1994;37(Suppl 2):S99-107.
23. Madsbad S, Lauritzen E, Faber OK, Binder C. The effect of residual beta-cell function on the development of diabetic retinopathy. Diabet Med. 1986;3:42-5.